Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2023-08-03 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
触发稳定股价措施启动条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Beijing Xinghao Pharmaceutical Co., Ltd. regarding the triggering of conditions to initiate stock price stabilization measures. It details the conditions under which these measures are activated, the specific triggering event (stock price falling below net asset value for 20 consecutive trading days), and the planned response including potential share repurchase. The document is an announcement about corporate actions related to stock price stabilization, not a financial report, earnings release, or regulatory certification. It is not a full report but a specific announcement about capital market measures. Therefore, it fits best under Capital/Financing Update (CAP). The document length is short (1152 characters), consistent with an announcement rather than a full report.
2023-08-03 Chinese
回购股份结果公告
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement regarding the company's share repurchase (buyback) program, including the repurchase plan, implementation results, disclosure during the repurchase period, and impact on the company. It specifies the number of shares repurchased, prices, funding sources, and regulatory compliance. The content focuses on the company's own shares transactions and does not contain financial statements or earnings data. Therefore, it fits the category of a Transaction in Own Shares (POS) filing, which covers share repurchase announcements and results.
2023-08-02 Chinese
回购进展情况公告
Transaction in Own Shares Classification · 100% confidence The document is titled as a "回购进展情况公告" which translates to "Repurchase Progress Announcement." It details the company's share repurchase plan, including the purpose, method, price limits, quantity, funding source, implementation period, and progress as of a specific date. The text includes specific figures on shares repurchased, amounts spent, and percentage of the plan completed. This is a clear report on the progress of a share buyback program, not a general financial report or earnings release. The document length is 1920 characters, which is relatively short but contains substantive information about the repurchase activity itself, not just an announcement of a report. Therefore, it fits best under the category of "Transaction in Own Shares (POS)" which covers reports of the company buying back or selling its own shares (share repurchase/issuance).
2023-07-31 Chinese
关于拟终止项目投资协议暨终止购买资产的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Xinghao Pharmaceutical Co., Ltd. regarding the termination of a project investment agreement and the termination of purchasing land use rights. It details the background of the investment, the reasons for termination, project progress, and the impact on the company. The document is a formal announcement about a corporate decision related to investment and asset purchase termination, not a financial report, earnings release, or regulatory certification. It does not contain financial statements or detailed financial data. The document length is 1583 characters, which is relatively short and consistent with an announcement. Therefore, it fits best into the category of a Regulatory Filing (RNS), which is a fallback category for miscellaneous corporate announcements that do not fit other specific categories.
2023-07-26 Chinese
第六届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 12th meeting of the 6th Board of Directors of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and references to other announcements for further details. There is no financial data, no report attached or published, and no mention of annual or interim reports. The content focuses on board meeting decisions and governance matters. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2023-07-26 Chinese
关于召开2023年第二次临时股东大会通知公告（提供网络投票）
Regulatory Filings Classification · 95% confidence The document is a notice announcing the convening of the 2023 second extraordinary general meeting of shareholders (临时股东大会) for Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), eligibility, agenda items, registration procedures, and contact information. There is no financial data, report content, or results of voting included. The document is an announcement about the meeting itself, not the meeting materials or voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA) only if it contained voting results, but since it does not, it is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the meeting. The document length is short (2056 characters), and it is not a report publication announcement. Hence, the best classification is Regulatory Filings (RNS).
2023-07-26 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.